Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar ...
EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight
DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...
DelveInsight Business Research, LLP: EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight
EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...
The Clinton Herald21h
TO YOUR GOOD HEALTH: Over-the-counter treatments don't help man's enlarged prostate
I am 71, and I recently saw my urologist for urinating a lot and not getting enough sleep. He performed a flow test and a ...